Invitation to Participate in STOP-PC Clinical Trial
04 mars 2024 08h17 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial which is now open for recruitment. Additional...
Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients
16 janv. 2024 08h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) and...
Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant
18 déc. 2023 08h10 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), unveils a state-of-the-art GMP Manufacturing Plant, a...
Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit.
28 nov. 2023 07h10 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its Chief Executive Officer (“CEO”),...
Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results
15 nov. 2023 09h00 HE
|
Oncotelic Therapeutics, Inc.
R&D cost remains essentially unchanged, while continuing expansion of our OT-101 clinical programs through our joint venture (“JV”)G&A cost significantly lower by over approximately $0.5...
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023
25 août 2023 07h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today it was featured in Life Sciences...
Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer
23 août 2023 07h10 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its joint venture partner, GMP...
Oncotelic Launches PR Chatbot
12 juin 2023 08h10 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), annouces the beta unveiling of a pioneering press...
Oncotelic Participating at 2023 BIO International Convention
16 mai 2023 08h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a pioneering developer of therapeutic interventions for rare and orphan diseases...
Oncotelic Launches PDAO SEC Chatbot
24 avr. 2023 07h30 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), , today announced the beta launch of a proprietary...